basiliximab + cyclosporine + mycophenolate mofetil + corticosteroids

This is a **combination immunosuppressive regimen** used primarily for the prophylaxis of acute rejection in patients receiving a kidney transplant. The regimen consists of four agents: - **Basiliximab**: a chimeric monoclonal antibody that selectively binds to the CD25 (alpha) subunit of the interleukin-2 receptor on activated T lymphocytes, thereby inhibiting IL-2-mediated T-cell proliferation and activation[1][2][3][5]. - **Cyclosporine**: a calcineurin inhibitor that suppresses cellular immunity by inhibiting T-cell activation through binding to cyclophilin and inhibiting the phosphatase activity of calcineurin, thus preventing transcription of IL-2[3]. - **Mycophenolate mofetil**: an inhibitor of inosine monophosphate dehydrogenase, impeding de novo purine synthesis and resulting in selective inhibition of lymphocyte proliferation. - **Corticosteroids**: broadly suppress immune responses by altering gene expression, reducing cytokine production, and inhibiting immune cell migration and activation. This multi-agent regimen is standard in renal transplantation and is designed for **synergistic suppression of rejection** while minimizing toxicity. Basiliximab is used for induction therapy, with cyclosporine, mycophenolate mofetil, and corticosteroids for maintenance immunosuppression. This regimen is typically indicated for patients with panel reactive antibody levels less than 80%, and has shown reduced incidence of acute rejection compared to placebo or dual therapy regimens[3]. The regimen is approved and widely used as immunosuppressive therapy in kidney transplantation; basiliximab is approved for use in combination with cyclosporine and corticosteroids, and commonly with mycophenolate mofetil[2][3].